SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000891293-17-000038
Filing Date
2017-03-28
Accepted
2017-03-28 16:42:56
Documents
8
Period of Report
2016-12-31
Effectiveness Date
2017-03-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2017definitiveproxystatem.htm DEF 14A 1277605
2 proxystate_image4a01.jpg GRAPHIC 17077
3 proxystate_image6a01.jpg GRAPHIC 2931
4 proxystate_image7a01.jpg GRAPHIC 3034
5 proxystate_image8a01.jpg GRAPHIC 3226
6 proxystate_image9a01.jpg GRAPHIC 3032
7 signaturea06.jpg GRAPHIC 20510
8 signaturea07.jpg GRAPHIC 20510
  Complete submission text file 0000891293-17-000038.txt   1365735
Mailing Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: WA | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-28386 | Film No.: 17719509
SIC: 2834 Pharmaceutical Preparations